- Home
- GDEV vs ATYR Comparison
GDEV vs ATYR Comparison
Compare GDEV & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- ATYR
- Stock Information
- Founded
- GDEV 2009
- ATYR 2005
- Country
- GDEV Cyprus
- ATYR United States
- Employees
- GDEV N/A
- ATYR N/A
- Industry
- GDEV EDP Services
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDEV Technology
- ATYR Health Care
- Exchange
- GDEV Nasdaq
- ATYR Nasdaq
- Market Cap
- GDEV 384.5M
- ATYR 451.3M
- IPO Year
- GDEV N/A
- ATYR 2015
- Fundamental
- Price
- GDEV $15.49
- ATYR $5.30
- Analyst Decision
- GDEV Buy
- ATYR Strong Buy
- Analyst Count
- GDEV 1
- ATYR 6
- Target Price
- GDEV $70.00
- ATYR $20.20
- AVG Volume (30 Days)
- GDEV 13.2K
- ATYR 3.7M
- Earning Date
- GDEV 09-03-2025
- ATYR 08-12-2025
- Dividend Yield
- GDEV N/A
- ATYR N/A
- EPS Growth
- GDEV N/A
- ATYR N/A
- EPS
- GDEV 1.38
- ATYR N/A
- Revenue
- GDEV $420,933,000.00
- ATYR N/A
- Revenue This Year
- GDEV N/A
- ATYR $960.85
- Revenue Next Year
- GDEV $17.39
- ATYR $1,283.47
- P/E Ratio
- GDEV $11.27
- ATYR N/A
- Revenue Growth
- GDEV N/A
- ATYR N/A
- 52 Week Low
- GDEV $8.60
- ATYR $1.58
- 52 Week High
- GDEV $42.76
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- GDEV 44.85
- ATYR 56.28
- Support Level
- GDEV $15.26
- ATYR $5.07
- Resistance Level
- GDEV $17.60
- ATYR $5.58
- Average True Range (ATR)
- GDEV 1.15
- ATYR 0.39
- MACD
- GDEV -0.14
- ATYR -0.04
- Stochastic Oscillator
- GDEV 19.14
- ATYR 64.20
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.